摘要
脑胶质瘤(glioma)是大脑和脊髓胶质细胞发生癌变后所产生原发性颅脑肿瘤,来自于神经上皮细胞,是最常见的恶性肿瘤,主要由于表皮生长因子受体(epidermal growth factor receptor,EGFR)突变所导致。脑胶质瘤细胞还能分泌血管内皮生长因子(vascular endothelial growth factor,VEGF)导致更加严重的后果。目前对于该病的治疗包括手术、放疗和化疗等手段,但也只能缓解症状,无法完全根治,而且经常复发。近些年来,关于药物治疗的研究一直没有停止。桑白皮(Morus alba L)为桑科植物桑(Morus alba L)的根皮,主要用于肺热喘咳痰,水饮停肺,胀满喘急的治疗,而从中提取的桑皮素(Mulberin)为主要活性成分。研究发现桑皮素对癌细胞中的EGF有一定的影响,进而影响EGFR的表达。桑皮素对VEGF也有一定的影响,因此可以通过影响EGF和VEGF来治疗脑胶质瘤。该文就脑胶质瘤的发展现状和桑皮素的研究及对EGF和VEGF的影响进行综述,并在此基础上提出了桑皮素治疗脑胶质瘤的新思路。
Glioma is the primary brain tumor generated by cancerous brain and spinal cord glial cells. It’s the most common malignant tumor,comes from neuroepithelial cells and is mainly caused by EGF receptor mutation. Glioma cells also secrete VEGF factors,which can lead to more serious consequences. Currently,the treatments for the disease include surgery,radiotherapy,chemotherapy and other means,however,it can only relieve the symptoms,be completely cured hardly and often relapse. In recent years,the researches of drug therapy have not been stopped. Morus alba L is the root bark of Morus alba L,which is mainly used for treating lung heat,wheezing and phlegm,stopping lung by drinking water,and wheezing and acute wheezing after swelling. The Mulberin extracted from Morus alba L is the mainly active ingredient. Studies have shown that Mulberin has a certain effect on EGF in cancer cells,which in turn affects the expression of EGF receptor. Mulberin also has a certain effect on VEGF,so it can be used to treat Glioma by affecting EGF and VEGF. This article reviewed the development status of Glioma,the research of Mulberin and its effect on EGF and VEGF. In the meantime,a new idea of treating Glioma with Mulberin is proposed based on above of conclusions.
作者
赵鹏慧
庞策
甄攀
ZHAO Peng-hui;PANG Ce;ZHEN Pan(Department of Pharmacy,Hebei North University,Zhangjiakou,075000,China;Institute of Applied Chemistry,Hebei North University,Zhangjiakou,075000,China)
出处
《神经药理学报》
2019年第5期44-49,共6页
Acta Neuropharmacologica
基金
河北省高等学校科学技术研究项目(No.ZD2016016)
2018年度河北北方学院一般项目(No.YB2018030)
